PARP6

Overview

PARP6 (Poly(ADP-Ribose) Polymerase 6) is a member of the PARP superfamily involved in mono-ADP-ribosylation. In cancer genomics, PARP6 has been identified as a candidate epigenetically silenced gene in muscle-invasive bladder cancer (MIBC), suggesting a potential tumor-suppressive or functional role whose loss may contribute to cancer progression.

Alterations observed in the corpus

  • PARP6 is epigenetically silenced in 26% of MIBC tumors (n=412); identified as a candidate functional contributor and potential therapeutic-vulnerability biomarker alongside LXN, NAPRT, and SPATC1L PMID:28988769.

Cancer types (linked)

  • MIBC (muscle-invasive bladder cancer): Epigenetic silencing in 26% of tumors in the TCGA BLCA 2017 cohort PMID:28988769.

Co-occurrence and mutual exclusivity

  • Co-silenced with LXN (27%), NAPRT (13%), and SPATC1L (19%) as a group of novel epigenetically silenced hits in MIBC PMID:28988769.

Therapeutic relevance

  • Candidate therapeutic-vulnerability biomarker in MIBC based on epigenetic silencing frequency PMID:28988769.

Open questions

  • Functional consequences of PARP6 silencing in bladder cancer remain to be characterized; whether silencing is driver or passenger is unresolved.

Sources

This page was processed by crosslinker on 2026-05-15.